AbFero to Receive € 2M Eurostars Funding for Parkinson’s Disease Therapy

AbFero Ltd., a subsidiary of UF startup AbFero Pharmaceuticals, Inc., a privately-held clinical-stage pharmaceutical company dedicated to treating diseases of iron overload, announced the funding of approximately € 2M from EUREKA Eurostars for the development of iron-chelating compounds including their lead agent, SP-420, as a disease-modifying therapy for Parkinson’s disease.

“This grant is an important step forward for AbFero as we test our portfolio of iron-chelating compounds in central nervous system indications,” said AbFero CEO Thomas Neenan. “With three Phase 1 clinical trials complete, this funding will accelerate our drive to a Phase 2 trial of SP-420 in Parkinson’s patients, for whom disease-modifying agents remain much needed.” 

Learn more about AbFero to Receive € 2M Eurostars Funding for Parkinson’s Disease Therapy.